Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients. The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated. These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality. Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, Blood and Marrow Transplantation Long-Term Management: Survivorship after Transplant, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT.
Currently more than 100,000 patients undergo blood and marrow transplantation (BMT) annually worldwide, a number which is steadily increasing. Long-term survival after BMT has improved significantly since its inception over 40 years ago, due to improved supportive care and early recognition of long-term complications. With broadening indications, more options for BMT, and improvement in survival, by 2020 there may be up to a million long-term survivors after BMT globally. Higher than average rates of second malignancies and cardiopulmonary, infectious, endocrine, and renal diseases, and bone loss or avascular necrosis amongst this population suggest that the rapidly swelling ranks of BMT survivors require more frequent screening and earlier interventions than the general population. The purpose of Blood and Marrow Transplantation Long-Term Management is to describe practical approaches to screening for and managing these late effects, with the goal of reducing preventable morbidity and mortality associated with BMT. This unique new book is the first to address the needs of the increasing population of long-term survivors after stem cell transplantation, making it a must-have resource for all oncologists, hematologists, and primary care physicians involved in the long-term management and care of BMT patients. Titles of related interest Thomas’ Hematopoietic Cell Transplantation, 4th edition Appelbaum, ISBN 9781405153485 Practical Stem Cell Transplantation Cant, ISBN 9781405134019 Mollison’s Blood Transfusion in Clinical Medicine, 12th edition Klein, ISBN 9781405199407
This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees.
Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients. The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated. These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality. Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, Blood and Marrow Transplantation Long-Term Management: Survivorship after Transplant, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT.
Developed by the Blood and Marrow Transplant team at Oregon Health & Science University Knight Cancer Institute, this pocket guide provides management guidelines for hematopoietic stem cell transplant patients from the moment of their initial consultation throughout the transplant process. It includes indications for transplant, essential details for patient/donor evaluation, recommendations for management of complications during and after transplant, and guidelines for long-term follow up as well as step-by-step instructions for common procedures and documentation guidelines. An essential tool for providers, this guide presents a multidisciplinary approach to information you will need to provide quality care for your patients.
Leading transplant physicians critically review and interpret twenty-one key clinical challenges in bone marrow/hematopoietic cell transplantation, and offer their best personal recommendations for treatment. Topics range from transplant strategies to complications of bone marrow transplantation, including a discussion of the indications, benefits, and the risks for a variety of leukemias, lymphomas, and solid tumors. The authors debate such contentious issues as the appropriateness of transplants in older patients, how many stem cells are sufficient for engraftment, and the pros and cons of umbilical cord blood transplantation. Up-to-date and clinically focused, Current Controversies in Bone Marrow Transplantation offers clinical oncologists, hematology/oncology fellows in training, and residents in internal medicine today's best ready reference and management guide for all their critical oncologic problems arising from the use of bone marrow/stem cell transplantation.
This text aims to provide simplified practical guidelines to start a hematopoietic stem cell transplantation unit which could be implemented in most centers and countries worldwide. The book also provides guidelines for existing transplantation units to upgrade their practice and implement new policies and procedures, in addition to developing therapies according to latest international standards and regulations. The book covers a wide range of practical implementation tools including HSCT program team structure, building inpatient and outpatient HSCT units, requisite laboratory support for transplantation program, practical aspects of stem cell collection and processing, HSCT program quality management, education and training, and data management. The book also addresses cost effectiveness and recommendations for establishing transplantation program in countries with limited resources. Written by group of internationally established experts in their corresponding hematopoietic stem cell transplantation fields, with contributions from many leaders of hematopoietic stem cell transplantation organizations, Establishing a Hematopoietic Stem Cell Transplantation Unit: A Practical Guide is an essential, practical resource for all members of the multidisciplinary hematopoietic stem cell transplantation team.
This book is a comprehensive and up-to-date compendium on all aspects of blood and marrow transplantation in children. After an introductory chapter describing the history of pediatric blood and marrow transplantation, subsequent chapters discuss pediatric-specific aspects of transplantation, including stem cell sources suitable for transplantation, preparative regimens, graft-versus-host disease, complications related to transplantation, and late effects. The role of blood and marrow transplantation in various specific pediatric diseases is then examined, and the closing chapter considers future directions. The authors are all internationally recognized experts and offer a largely evidence-based consensus on etiology, biology, and treatment. This handbook has far-reaching applicability to the clinical diagnosis and management of pediatric diseases that are treatable with blood and marrow transplantation and will prove invaluable to specialists, generalists, and trainees alike.
An up-to-date overview of blood and marrow transplantations, the book discusses in detail Indication to transplantation and pre-transplant considerations. An outlook on the latest developments and their future aspects is included, while problems and pre- and post-transplant complications are fully explored.
Chronic graft versus host disease (GVHD) is the most common complication of allogenic bone marrow transplantation. Because of the protracted clinical course of chronic GVHD, transplant centers and hematology/oncology offices are inadequately equipped to manage these immuno-incompetent patients with a multi-system disorder. Practitioners need to be able to recognize and effectively manage chronic GVHD as a late effect of more than half of allogenic transplantations. The text is oriented for the clinician, with chapters covering staging, organ site and system-specific manifestations, treatment options, and supportive care. Drs. Georgia B. Vogelsang and Steven Z. Pavletic have been pioneers in the recognition of the multi-organ complexity of this disease and have gathered the input of a variety of subspecialist physicians for this book. This book fills the gap in practical literature on chronic GVHD, providing a comprehensive, up-to-date, and clinically relevant resource for anyone who deals with cancer patients post-transplant.
This text offers information on care of patients undergoing transplant procedures including heart, renal, liver, bone marrow, and small bowel. It includes a chapter on care of organ donors. Up-to-date chapters offer information on ethical implications and legislative aspects of organ transplantation. Also included is research in transplantation and recommendations for further study in this field.
The first book on clinical guide to transplantation in lymphoma to present cutting edge knowledge on how to integrate, transplantation and novel therapies in patients with lymphoid malignancies Provides practical management guidance on how to integrate, transplantation and novel therapies in patients with lymphoid malignancies Covers an overview of transplantation in lymphoma, and management of the lymphoid malignancies Discusses organizational aspects of transplant patients and managing a transplant program Appendices provide practical quick-reference information on follow-up after autologous and allogenic stem cell transplantation in lymphoma
